Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 25037835 |
PL |
67 | 2 |
COVID-19, Aspartate aminotransferase increased, Dehydration, Malignant neoplasm progression, Acute kidney injury, Blood creatinine increased, Diarrhoea, Alanine aminotransferase increased, Vomiting, Nausea, |
||||
ZOLEDRONIC ACID, ABEMACICLIB, ABEMACICLIB, FULVESTRANT, DENOSUMAB, |
||||
| 502 | 25037978 |
CA |
73 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 503 | 25038031 |
NL |
76 | 1 |
Malignant neoplasm progression, |
||||
TRIPTORELIN PAMOATE, TRIPTORELIN PAMOATE, TRIPTORELIN PAMOATE, |
||||
| 504 | 25038065 |
RU |
70 | 2 |
Malignant neoplasm progression, Off label use, |
||||
LANREOTIDE ACETATE, LANREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE, |
||||
| 505 | 25038101 |
CA |
51 | 2 |
Ovarian cancer, Malignant neoplasm progression, Off label use, |
||||
LETROZOLE, LETROZOLE TABLETS, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, CARBOPLATIN, BEVACIZUMAB, FENTANYL, |
||||
| 506 | 25038113 |
US |
1 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 507 | 25038152 |
US |
59 | 2 |
Malignant neoplasm progression, |
||||
ABEMACICLIB, ABEMACICLIB, |
||||
| 508 | 25038168 |
JP |
6 | 1 |
Malignant neoplasm progression, Tumour lysis syndrome, Acute kidney injury, Diarrhoea, Taste disorder, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, |
||||
| 509 | 25038244 |
US |
1 | |
Malignant neoplasm progression, |
||||
AXITINIB, |
||||
| 510 | 25038275 |
US |
72 | 2 |
Breast cancer female, Malignant neoplasm progression, Metastases to bone, |
||||
PALBOCICLIB, |
||||
| 511 | 25038309 |
US |
81 | 2 |
Malignant neoplasm progression, Nausea, Nausea, Vomiting, Vomiting, Diarrhoea, Diarrhoea, Nausea, Vomiting, Diarrhoea, |
||||
PEMBROLIZUMAB, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, |
||||
| 512 | 25038488 |
US |
1 | |
Malignant neoplasm progression, Prostatic specific antigen increased, Fatigue, |
||||
ENZALUTAMIDE, TALAZOPARIB, |
||||
| 513 | 25038683 |
JP |
||
Malignant neoplasm progression, |
||||
OLAPARIB, BEVACIZUMAB, |
||||
| 514 | 25029078 |
US |
||
Product prescribing issue, Palpitations, Cardiac disorder, Malignant neoplasm progression, Product dose omission issue, Sensory processing sensitivity, Arterial injury, |
||||
ROSUVASTATIN, |
||||
| 515 | 25029470 |
JP |
||
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED DISODIUM, PEMETREXED, DOCETAXEL, DOCETAXEL ANHYDROUS, RAMUCIRUMAB, PACLITAXEL, GEMCITABINE HYDROCHLORIDE, ATEZOLIZUMAB, |
||||
| 516 | 25029727 |
NO |
45 | 1 |
Pneumonitis, Haemophilus infection, Rales, Type 1 diabetes mellitus, Malignant neoplasm progression, Pyrexia, Antithrombin III decreased, |
||||
NIVOLUMAB, INFLIXIMAB, |
||||
| 517 | 25029866 |
RS |
||
Anaemia, Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 518 | 25030264 |
CA |
70 | 2 |
Breast cancer recurrent, Hyperhidrosis, Malignant neoplasm progression, Toxicity to various agents, Postoperative wound complication, Rheumatoid arthritis, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, FULVESTRANT, TAMOXIFEN CITRATE, |
||||
| 519 | 25030533 |
US |
4 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, FLUOROURACIL, CISPLATIN, |
||||
| 520 | 25030551 |
IT |
59 | 2 |
Hepatic failure, Metastases to peritoneum, Malignant neoplasm progression, Thrombocytopenia, Anaemia, Gastrointestinal toxicity, Condition aggravated, Ascites, Diarrhoea, Oedema peripheral, Alanine aminotransferase increased, Aspartate aminotransferase increased, |
||||
PEMETREXED, PEMETREXED DISODIUM, CISPLATIN, PEMBROLIZUMAB, SELPERCATINIB, SELPERCATINIB, SELPERCATINIB, |
||||
| 521 | 25030565 |
US |
||
Malignant neoplasm progression, Colitis, Wrist fracture, Off label use, Product use issue, |
||||
IVOSIDENIB, IVOSIDENIB, IVOSIDENIB, IVOSIDENIB, IVOSIDENIB, |
||||
| 522 | 25030630 |
US |
74 | 1 |
Prostate cancer metastatic, Malignant neoplasm progression, Prostate cancer, Bone pain, Drug ineffective, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, ENZALUTAMIDE, |
||||
| 523 | 25030637 |
US |
64 | 1 |
Non-small cell lung cancer, Malignant neoplasm progression, Drug ineffective, T-cell lymphoma, Product use in unapproved indication, |
||||
DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DOCETAXEL, DOCETAXEL ANHYDROUS, CISPLATIN, RITUXIMAB, PREDNISONE, PEMBROLIZUMAB, FLUDARABINE PHOSPHATE, BRENTUXIMAB VEDOTIN, AXICABTAGENE CILOLEUCEL, |
||||
| 524 | 25031048 |
DE |
||
Respiratory failure, Pneumonia fungal, Malignant neoplasm progression, General physical health deterioration, Cardiac failure, Anaphylactic reaction, Atrial fibrillation, Atypical pneumonia, Pneumonia, Tumour lysis syndrome, Respiratory acidosis, Lymphadenopathy mediastinal, Liver disorder, Blood bilirubin increased, Splenomegaly, Pyrexia, |
||||
RITUXIMAB, PIRTOBRUTINIB, |
||||
| 525 | 25031410 |
CO |
||
Malignant neoplasm progression, |
||||
GOSERELIN, GOSERELIN, |
||||
| 526 | 25031634 |
JP |
76 | 1 |
Immune-mediated renal disorder, Malignant neoplasm progression, Pyrexia, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, |
||||
| 527 | 25031698 |
US |
||
Non-small cell lung cancer, Malignant neoplasm progression, |
||||
BINIMETINIB, ENCORAFENIB, |
||||
| 528 | 25031809 |
DO |
2 | |
Death, Breast cancer, Malignant neoplasm progression, General physical health deterioration, |
||||
RIBOCICLIB, |
||||
| 529 | 25031818 |
TZ |
43 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Metastases to central nervous system, Seizure, Brain oedema, |
||||
LAPATINIB, LAPATINIB, LAPATINIB, CAPECITABINE, TRASTUZUMAB, TRASTUZUMAB, |
||||
| 530 | 25031873 |
US |
74 | 1 |
Malignant neoplasm progression, Prostate cancer, Metastases to bone, Metastases to lymph nodes, Fatigue, Bone pain, Nausea, Therapy non-responder, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, DOCETAXEL, DOCETAXEL ANHYDROUS, CABAZITAXEL, |
||||
| 531 | 25032042 |
US |
64 | 2 |
Brain oedema, Blood brain barrier defect, Headache, Malignant neoplasm progression, Breast cancer metastatic, |
||||
PALBOCICLIB, LACOSAMIDE, LACOSAMIDE, |
||||
| 532 | 25032072 |
BR |
72 | 2 |
Diarrhoea, Asthenia, Immunodeficiency, Weight decreased, Malignant neoplasm progression, |
||||
CETUXIMAB, |
||||
| 533 | 25032324 |
JP |
72 | 1 |
Malignant neoplasm progression, Immune-mediated hypothyroidism, Interstitial lung disease, Malaise, Diarrhoea, Dysphonia, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 534 | 25032330 |
FR |
71 | 1 |
Death, Malignant neoplasm progression, Thrombotic microangiopathy, Acute kidney injury, |
||||
TRIPTORELIN, CABAZITAXEL, ENZALUTAMIDE, DOCETAXEL, DOCETAXEL ANHYDROUS, ABIRATERONE ACETATE, ABIRATERONE, BICALUTAMIDE, |
||||
| 535 | 25032407 |
JP |
75 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 536 | 25032417 |
JP |
31 | 1 |
Malignant neoplasm progression, Cholangitis sclerosing, Erythema, Alanine aminotransferase increased, Malaise, |
||||
PEMBROLIZUMAB, |
||||
| 537 | 25032499 |
RU |
65 | |
Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 538 | 25032506 |
CL |
2 | |
Malignant melanoma, Malignant neoplasm progression, Lymphadenopathy, Lymph nodes scan abnormal, Skin lesion, Bladder dilatation, Hypermetabolism, Skin hypertrophy, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, TRAMETINIB, |
||||
| 539 | 25032740 |
CA |
57 | 2 |
Breast cancer, Malignant neoplasm progression, Therapeutic response decreased, |
||||
EVEROLIMUS, ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 540 | 25032849 |
JP |
84 | 1 |
Death, Intussusception, Malignant neoplasm progression, Pneumonia bacterial, Interstitial lung disease, Diarrhoea, |
||||
PEMBROLIZUMAB, NIVOLUMAB, NIVOLUMAB, |
||||
| 541 | 25032874 |
MX |
62 | 2 |
Death, Pleural effusion, Decreased appetite, Malignant neoplasm progression, Off label use, |
||||
CETUXIMAB, PACLITAXEL, LINAGLIPTIN, DAPAGLIFLOZIN, ERYTHROPOIETIN, TELMISARTAN, |
||||
| 542 | 25032893 |
JP |
5 | 2 |
Neuropathy peripheral, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 543 | 25032928 |
JP |
6 | |
Appendicitis perforated, Malignant neoplasm progression, Peritonitis, |
||||
PEMBROLIZUMAB, FLUOROURACIL, CISPLATIN, |
||||
| 544 | 25033191 |
US |
2 | |
Herpes zoster, Metastases to central nervous system, HER2 positive breast cancer, Malignant neoplasm progression, Hypokalaemia, Diarrhoea, Dermatitis, Arthralgia, Asthenia, Intracranial mass, COVID-19, Drug eruption, Palmar-plantar erythrodysaesthesia syndrome, Myalgia, Pain in extremity, Dry skin, Skin fissures, |
||||
LETROZOLE, LETROZOLE TABLETS, TUCATINIB, TUCATINIB, TUCATINIB, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, ADO-TRASTUZUMAB EMTANSINE, CAPECITABINE, CAPECITABINE, CAPECITABINE, CAPECITABINE, PERTUZUMAB, PERTUZUMAB, PERTUZUMAB, PERTUZUMAB, |
||||
| 545 | 25033286 |
JP |
7 | 1 |
Malignant neoplasm progression, Cardiac failure, Hypertension, Proteinuria, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 546 | 25033290 |
JP |
2 | |
Malignant neoplasm progression, Female genital tract fistula, |
||||
PEMBROLIZUMAB, BEVACIZUMAB, |
||||
| 547 | 25033385 |
CA |
55 | 2 |
Malignant neoplasm progression, Breast cancer, Drug ineffective, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, ERIBULIN MESYLATE, TAMOXIFEN CITRATE, |
||||
| 548 | 25033406 |
US |
2 | |
Malignant neoplasm progression, Toxicity to various agents, Ill-defined disorder, Neuropathy peripheral, Diabetes mellitus, Rash, Malaise, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 549 | 25033412 |
JP |
7 | 2 |
Cardiac failure, Malignant neoplasm progression, Deep vein thrombosis, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 550 | 25026898 |
JP |
8 | 1 |
Malignant neoplasm progression, Pulmonary fibrosis, |
||||
PEMBROLIZUMAB, |
||||
| 551 | 25028563 |
GB |
19 | 1 |
Malignant neoplasm progression, Pancreatitis acute, Disease progression, Jaundice cholestatic, Off label use, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, CABOZANTINIB, CABOZANTINIB, PREGABALIN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, MORPHINE SULFATE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, FUROSEMIDE, GLYCOPYRROLATE, LANSOPRAZOLE, PREGABALIN, PREGABALIN, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, LORAZEPAM, MIDAZOLAM, MIDAZOLAM HYDROCHLORIDE, MORPHINE SULFATE, |
||||
| 552 | 25028630 |
JP |
85 | 1 |
Lung neoplasm malignant, Decreased appetite, Malignant neoplasm progression, Interstitial lung disease, |
||||
CAPMATINIB, CAPMATINIB, CAPMATINIB, |
||||
| 553 | 25028877 |
CA |
||
Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 554 | 25021508 |
US |
2 | |
Breast cancer metastatic, Malignant neoplasm progression, |
||||
RIBOCICLIB, PALBOCICLIB, FULVESTRANT, |
||||
| 555 | 25021832 |
JP |
8 | 2 |
Acute kidney injury, Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 556 | 25022176 |
JP |
38 | |
Pulmonary toxicity, Malignant neoplasm progression, Small cell lung cancer, Pulmonary toxicity, |
||||
OSIMERTINIB, OSIMERTINIB, OSIMERTINIB, CISPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, BEVACIZUMAB, CARBOPLATIN, CARBOPLATIN, PACLITAXEL, DOCETAXEL, DOCETAXEL ANHYDROUS, RAMUCIRUMAB, ETOPOSIDE, |
||||
| 557 | 25022536 |
JP |
88 | 1 |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, NIVOLUMAB, |
||||
| 558 | 25022709 |
JP |
8 | 1 |
Delirium, Malignant neoplasm progression, Platelet count decreased, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 559 | 25023202 |
DE |
78 | 1 |
Malignant neoplasm progression, Sepsis, General physical health deterioration, Malignant neoplasm progression, Neutropenic infection, Febrile infection, Pneumonia, Splenomegaly, Granulocyte percentage decreased, Haematocrit decreased, Mean cell haemoglobin increased, Mean cell haemoglobin concentration increased, Mean platelet volume decreased, Monocyte count increased, Platelet distribution width decreased, Plateletcrit decreased, Red blood cell count decreased, Platelet count decreased, Haemoglobin decreased, Lymphocytosis, |
||||
LENALIDOMIDE, PIRTOBRUTINIB, PIRTOBRUTINIB, PIRTOBRUTINIB, RITUXIMAB, BISOPROLOL FUMARATE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, ACYCLOVIR, |
||||
| 560 | 25023209 |
SE |
59 | 2 |
Malignant neoplasm progression, Pyrexia, Vomiting, Hyponatraemia, Gastritis fungal, Fungal oesophagitis, |
||||
NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 561 | 25023394 |
DE |
1 | |
Malignant neoplasm progression, |
||||
ABIRATERONE ACETATE, ABIRATERONE, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 562 | 25023398 |
DE |
1 | |
Malignant neoplasm progression, |
||||
ABIRATERONE ACETATE, ABIRATERONE, DOCETAXEL, DOCETAXEL ANHYDROUS, ENZALUTAMIDE, APALUTAMIDE, |
||||
| 563 | 25023399 |
DE |
1 | |
Malignant neoplasm progression, |
||||
ABIRATERONE ACETATE, ABIRATERONE, DOCETAXEL, DOCETAXEL ANHYDROUS, ENZALUTAMIDE, |
||||
| 564 | 25023489 |
DE |
||
Thrombocytopenia, Atrial fibrillation, Malignant neoplasm progression, Hypertension, Acquired gene mutation, |
||||
ACALABRUTINIB, RITUXIMAB, ACALABRUTINIB, |
||||
| 565 | 25023572 |
PL |
67 | |
Dehydration, Acute kidney injury, Blood creatinine increased, COVID-19, Aspartate aminotransferase increased, Malignant neoplasm progression, Diarrhoea, Alanine aminotransferase increased, Vomiting, Nausea, |
||||
FULVESTRANT, FULVESTRANT, ABEMACICLIB, ABEMACICLIB, ZOLEDRONIC ACID, DENOSUMAB, |
||||
| 566 | 25023603 |
DE |
60 | 2 |
Neuropathy peripheral, Proteinuria, Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, FLUOROURACIL, RAMUCIRUMAB, PACLITAXEL, |
||||
| 567 | 25023973 |
FR |
71 | 2 |
Malignant neoplasm progression, General physical condition abnormal, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, DOSTARLIMAB, DOSTARLIMAB, |
||||
| 568 | 25024180 |
US |
2 | |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 569 | 25024204 |
US |
44 | 2 |
Gastrointestinal stromal tumour, Metastases to liver, Metastases to spine, Malignant neoplasm progression, Drug intolerance, Product use in unapproved indication, |
||||
IMATINIB, IMATINIB, EVEROLIMUS, EVEROLIMUS TABLETS, EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
| 570 | 25024229 |
|||
Thrombocytopenia, Metastases to lymph nodes, Malignant neoplasm progression, Squamous cell carcinoma, |
||||
RUXOLITINIB, RUXOLITINIB, |
||||
| 571 | 25024542 |
IN |
21 | 1 |
Malignant neoplasm progression, Product use in unapproved indication, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 572 | 25024575 |
ES |
70 | 1 |
Malignant neoplasm progression, Pancytopenia, |
||||
CETUXIMAB, CARBOPLATIN, FLUOROURACIL, |
||||
| 573 | 25024816 |
ES |
2 | |
Malignant neoplasm progression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TOPOTECAN, |
||||
| 574 | 25024821 |
IN |
28 | 1 |
Hepatic encephalopathy, Malignant neoplasm progression, Drug ineffective for unapproved indication, Pancytopenia, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, BENDAMUSTINE HCL, |
||||
| 575 | 25025216 |
CN |
58 | 2 |
Neuroendocrine tumour, Malignant neoplasm progression, Type 2 diabetes mellitus, Diabetes mellitus inadequate control, Decreased appetite, Abdominal distension, Abdominal pain, Asthenia, Back pain, Blood glucose increased, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, DENOSUMAB, CALCITRIOL, CALCITRIOL CAPSULES 0.25 MCG, CALCITRIOL CAPSULES 0.5 MCG, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, FENTANYL, MORPHINE, |
||||
| 576 | 25025327 |
US |
80 | 2 |
Malignant neoplasm progression, |
||||
PALBOCICLIB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, VITAMIN C, |
||||
| 577 | 25025348 |
JP |
6 | 1 |
Malignant neoplasm progression, Drug ineffective, |
||||
PEMBROLIZUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 578 | 25025407 |
JP |
50 | 2 |
Brain oedema, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 579 | 25025595 |
TR |
67 | 1 |
Malignant neoplasm progression, Hot flush, |
||||
ENZALUTAMIDE, ENZALUTAMIDE, LEUPROLIDE, |
||||
| 580 | 25031188 |
68 | 2 | |
Malignant neoplasm progression, |
||||
COLLAGENASE SANTYL, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, LEVOTHYROXINE, METHOCARBAMOL, METHOCARBAMOL TABLETS, PANTOPRAZOLE, |
||||
| 581 | 25016059 |
GR |
||
Acute lymphocytic leukaemia, Breast cancer metastatic, Breast cancer recurrent, Disease progression, Malignant neoplasm progression, Second primary malignancy, |
||||
BEVACIZUMAB, EVEROLIMUS, ANASTROZOLE, ANASTROZOLE TABLETS, CAPECITABINE, CARBOPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOCETAXEL, DOCETAXEL ANHYDROUS, EPIRUBICIN HYDROCHLORIDE, EXEMESTANE, FULVESTRANT, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, PACLITAXEL, PACLITAXEL, TAMOXIFEN CITRATE, |
||||
| 582 | 25016707 |
JP |
77 | 1 |
Malignant neoplasm progression, Neutropenia, Anaemia, |
||||
PEMBROLIZUMAB, |
||||
| 583 | 25016975 |
BE |
63 | 2 |
Pulmonary vasculitis, Organising pneumonia, Malignant neoplasm progression, Interstitial lung disease, |
||||
DENOSUMAB, LETROZOLE, LETROZOLE TABLETS, ABEMACICLIB, |
||||
| 584 | 25016978 |
CA |
2 | |
Death, Malignant neoplasm progression, |
||||
CALCIUM CARBONATE, ANTACID, CALCIUM CARBONATE, ANTACID, DEXPANTHENOL, ERGOCALCIFEROL, FULVESTRANT, OLAPARIB, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM, |
||||
| 585 | 25017253 |
CA |
66 | 2 |
Malignant neoplasm progression, Off label use, |
||||
BEVACIZUMAB, TISOTUMAB VEDOTIN, PEMBROLIZUMAB, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 586 | 25017388 |
US |
1 | |
Neuropathy peripheral, Parkinson^s disease, Mental impairment, Choking, Dementia, Malignant neoplasm progression, Dysphonia, Decreased appetite, Weight decreased, Fatigue, General physical health deterioration, Superficial injury of eye, Gait disturbance, Lip disorder, Rhinorrhoea, Restless legs syndrome, |
||||
CABOZANTINIB, CABOZANTINIB, |
||||
| 587 | 25017601 |
GR |
16 | 1 |
Contraindicated product administered, Glioma, Malignant neoplasm progression, |
||||
SOMATROPIN, |
||||
| 588 | 25018321 |
US |
||
Malignant neoplasm progression, Fatigue, Constipation, |
||||
IVOSIDENIB, |
||||
| 589 | 25019046 |
CN |
40 | |
Malignant neoplasm progression, Condition aggravated, Drug ineffective, |
||||
GEFITINIB, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 590 | 25019217 |
CN |
55 | 2 |
Hepatic failure, Malignant neoplasm progression, Ascites, Hepatic cirrhosis, Drug ineffective, |
||||
ABEMACICLIB, |
||||
| 591 | 25019276 |
JP |
8 | 2 |
Malignant neoplasm progression, Skin disorder, Therapeutic product effect incomplete, |
||||
PEMBROLIZUMAB, |
||||
| 592 | 25019491 |
DE |
55 | 1 |
Malignant neoplasm progression, Drug ineffective for unapproved indication, |
||||
CAPECITABINE, |
||||
| 593 | 25020209 |
RU |
53 | 2 |
Hemiparesis, Epilepsy, Malignant neoplasm progression, Neuropathy peripheral, |
||||
CARBOPLATIN, CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, CAPECITABINE, BEVACIZUMAB, BEVACIZUMAB, CISPLATIN, |
||||
| 594 | 25020773 |
US |
||
Cataract, Pyrexia, Hyperhidrosis, Pain, Back pain, Sleep disorder, Anxiety, Sciatica, Pain in extremity, Arthralgia, Musculoskeletal pain, Influenza, Neck pain, Malignant neoplasm progression, |
||||
FULVESTRANT, FULVESTRANT, PALBOCICLIB, |
||||
| 595 | 25011786 |
TR |
79 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, ZOLEDRONIC ACID, |
||||
| 596 | 25012294 |
GB |
||
Deep vein thrombosis, Malignant neoplasm progression, Renal impairment, Therapy partial responder, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 597 | 25012929 |
CN |
60 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, OSIMERTINIB, |
||||
| 598 | 25013538 |
CN |
51 | |
Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 599 | 25013611 |
CH |
1 | |
Gastroenteropancreatic neuroendocrine tumour disease, Malignant neoplasm progression, Off label use, |
||||
LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, LUTETIUM LU 177 DOTATATE, |
||||
| 600 | 25013807 |
US |
||
Malignant neoplasm progression, |
||||
VORASIDENIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28